DISCLOSURE: This site receives compensation from featured companies, which may influence rankings. Read Advertising Disclosure
Semaglutide vs. Tirzepatide: Which GLP-1 Medication May Be Right for You?
Semaglutide (Wegovy) and tirzepatide (Zepbound) are the two most prominent GLP-1-based weight loss medications available today, but they work through different mechanisms and produce different levels of results. This comparison may help you understand the key differences in efficacy, cost, side effects, and availability so you can have a more informed conversation with your healthcare provider.
| Feature | semaglutide | tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single target) | Dual GIP/GLP-1 receptor agonist (two targets) |
| Avg Weight Loss | ~15-17% of body weight (studies suggest) | ~20-25% of body weight (studies suggest) |
| Dosing | Weekly injection (2.4mg maintenance dose) | Weekly injection (up to 15mg maintenance dose) |
| Price Range | $199-$349/mo through telehealth providers | $299-$449/mo through telehealth providers |
| Common Side Effects | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting, constipation (similar profile) |
| Oral Option Available | Yes — Wegovy Pill (25mg daily, approved Dec 2025) | No oral version currently approved |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Telehealth Availability | Widely available (Ro, Hims, Noom, and others) | Available but fewer provider options (Ro, Calibrate, LillyDirect) |
Choose semaglutide if...
Semaglutide may be a better fit for patients who want the most clinically studied GLP-1 option with a long track record, prefer the flexibility of choosing between an injection and an oral pill, are looking for a lower price point, or have cardiovascular risk factors that may benefit from semaglutide's demonstrated heart health data.
Choose tirzepatide if...
Tirzepatide may be a better fit for patients who want to maximize potential weight loss and are willing to pay a premium, have not achieved desired results with semaglutide alone, or are interested in the dual-mechanism approach that targets both GIP and GLP-1 pathways for potentially enhanced metabolic benefits.
The Verdict
Both semaglutide and tirzepatide are effective GLP-1-based weight loss medications with strong clinical evidence. Tirzepatide appears to produce greater average weight loss in clinical trials, but it comes at a higher cost and with fewer telehealth provider options. Semaglutide offers more flexibility with its oral formulation, broader availability, and lower pricing. Ultimately, the best choice depends on your individual health profile, budget, and treatment goals — a conversation with a licensed provider is the best way to determine which medication may be right for you.